Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies

Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies

Background: Prucalopride (1 or 2 mg once daily) is approved for treating adults with chronic idiopathic constipation (CIC). Objectives: We determined the effect of age, body mass index (BMI), and renal function on the efficacy and safety of prucalopride in adults with CIC. Design: Data were pooled f...

Full description

Saved in:
Bibliographic Details
Main Authors: Anthony Lembo, Kyle Staller, Mena Boules, Paul Feuerstadt, William Spalding, André Gabriel, Ashraf Youssef, Yunlong Xie, Brian Terreri, Brooks D. Cash
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848241299731
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items